Cancer Family
Secondary Malignant Neoplasm
CI-CAN-00000346SMNExplore in graph →
4,275 active trials56 approved drugs532 evidence items
- NCIt
- C4968
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000346SMNExplore in graph →
Clinical trials
14,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,961)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03902951 | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | active not recruiting | Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05737199 | Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma | active not recruiting | Phase 2 | 21 | Niigata University Medical & Dental HospitalOTHER | 1 | Feb 5, 2026 |
| NCT03808662 | Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung | active not recruiting | Phase 2 | 107 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 4, 2026 | clinicaltrials |
| NCT04762953 | Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis(STOPGAP) | active not recruiting | Phase 2 | 40 | University of California, IrvineOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04454437 | Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments | active not recruiting | Phase 2 | 80 | Gilead SciencesINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05621707 | Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)(RICE) | active not recruiting | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07380633 | Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial | active not recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04645680 | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy(DIET) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT03474497 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | active not recruiting | Phase 1 / Phase 2 | 18 | Megan Daly, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05113186 | Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative(LENVABLA) | active not recruiting | Phase 2 | 32 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02769520 | Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck | active not recruiting | Phase 2 | 27 | Assuntina G. Sacco, MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05366166 | Pembrolizumab Plus Olaparib in LA-HNSCC | active not recruiting | Phase 2 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03368729 | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | University of Alabama at BirminghamOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03468218 | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer | active not recruiting | Phase 2 | 36 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05036434 | Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma(ACCOMPLISH) | active not recruiting | Phase 2 | 30 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03879577 | Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer | active not recruiting | Phase 2 | 53 | University of ChicagoOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03257163 | Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer | active not recruiting | Phase 2 | 40 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03546582 | SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma(KEYSTROKE) | active not recruiting | Phase 2 | 86 | RTOG Foundation, Inc.OTHER | 2 | Jan 20, 2026 | clinicaltrials |
| NCT02473536 | Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC | active not recruiting | Phase 1 / Phase 2 | 25 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04183166 | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | active not recruiting | Phase 1 / Phase 2 | 80 | TransgeneINDUSTRY | 4 | Jan 16, 2026 | clinicaltrials |
| NCT05312710 | Safety and Efficacy of APG-157 in Head and Neck Cancer | active not recruiting | Phase 2 | 24 | Aveta Biomics, Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04448886 | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | active not recruiting | Phase 2 | 110 | Ana C Garrido-Castro, MDOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03891784 | Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors | active not recruiting | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04229459 | Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. | active not recruiting | Phase 2 | 12 | Baruch BrennerOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04539808 | NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer | active not recruiting | Phase 2 | 42 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05239533 | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | active not recruiting | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05594290 | Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery(MERCURY) | active not recruiting | Phase 2 | 36 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06232564 | A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs(PELICAN) | active not recruiting | Phase 2 | 20 | Imperial College LondonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04028167 | Induction FLOT With CROSS CRT for Esophageal Cancer | active not recruiting | Phase 2 | 40 | University of Colorado, DenverOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04777071 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | active not recruiting | Phase 2 | 141 | University of WashingtonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05504252 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2) | active not recruiting | Phase 2 | 80 | University Hospital, AkershusOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT05023967 | Metformin and Nightly Fasting in Women With Early Breast Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT03090165 | Ribociclib and Bicalutamide in AR+ TNBC | active not recruiting | Phase 1 / Phase 2 | 37 | Kari WisinskiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04762979 | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | active not recruiting | Phase 2 | 44 | Marina N SharifiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05858229 | Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. | active not recruiting | Phase 1 / Phase 2 | 12 | Sherrif IbrahimOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT03600233 | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | active not recruiting | Phase 2 | 34 | TaiRx, Inc.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03673124 | Ribociclib and Letrozole Treatment in Ovarian Cancer | active not recruiting | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients(RAMP201J) | active not recruiting | Phase 2 | 16 | Verastem, Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05363631 | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Mohammed MilhemOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT07267286 | Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005） | active not recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05433116 | Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC | active not recruiting | Phase 2 | 50 | Universität des SaarlandesOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05659251 | Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03571633 | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer(BREASTIMMU02) | active not recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Nov 26, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 5, 2026source: clinicaltrials